| Issue Date | Title | Author(s) |
| 2021-03-03 | A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma | Cheung, BB; Kleynhans, A; Mittra, R; Kim, PY; Holien, JK; Nagy, Z; Ciampa, OC; Seneviratne, JA; Mayoh, C; Raipuria, M; Gadde, S; Massudi, H; Wong, IPL; Tan, O; Gong, A; Suryano, A; Diakiw, SM; Liu, B; Arndt, GM; Liu, T; Kumar, N; Sangfelt, O; Zhu, S; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM |
| 2021-03-25 | An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability | Nagy, Z; Seneviratne, JA; Kanikevich, M; Chang, W; Mayoh, C; Venkat, P; Du, Y; Jiang, C; Salib, A; Koach, J; Carter, DR; Mittra, R; Liu, T; Parker, MW; Cheung, BB; Marshall, GM |
| 2024-11 | Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma. | Seneviratne, JA; Ravindrarajah, D; Carter, DR; Zhai, V; Lalwani, A; Krishan, S; Balachandran, A; Ng, E; Pandher, R; Wong, M; Nero, TL; Wang, S; Norris, MD; Haber, M; Liu, T; Parker, MW; Cheung, BB; Marshall, GM |
| 2021-06-01 | Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells. | Thoms, JAI; Truong, P; Subramanian, S; Knezevic, K; Harvey, G; Huang, Y; Seneviratne, JA; Carter, DR; Joshi, S; Skhinas, J; Chacon, D; Shah, A; de Jong, I; Beck, D; Gottgens, B; Larsson, J; Wong, JWH; Zanini, F; Pimanda, JE |
| 2019-11-01 | Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface | Koach, J; Holien, JK; Massudi, H; Carter, DR; Ciampa, OC; Herath, M; Lim, T; Seneviratne, JA; Milazzo, G; Murray, JE; McCarroll, JA; Liu, B; Mayoh, C; Keenan, B; Stevenson, BW; Gorman, MA; Bell, JL; Doughty, L; Hüttelmaier, S; Oberthuer, A; Fischer, M; Gifford, AJ; Liu, T; Zhang, X; Zhu, S; Gustafson, WC; Haber, M; Norris, MD; Fletcher, JI; Perini, G; Parker, MW; Cheung, BB; Marshall, GM |
| 2024-10-14 | Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis. | Cheung, BB; Mittra, R; Murray, J; Wang, Q; Seneviratne, JA; Raipuria, M; Wong, IPL; Restuccia, D; Gifford, A; Salib, A; Sutton, S; Huang, L; Ferdowsi, PV; Tsang, J; Sekyere, E; Mayoh, C; Luo, L; Brown, DL; Stow, JL; Zhu, S; Young, RJ; Solomon, BJ; Chappaz, S; Kile, B; Kueh, A; Herold, MJ; Hilton, DJ; Liu, T; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM |
| 2023-04-01 | Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. | Seneviratne, JA; Carter, DR; Mittra, R; Gifford, A; Kim, PY; Luo, J-S; Mayoh, C; Salib, A; Rahmanto, AS; Murray, J; Cheng, NC; Nagy, Z; Wang, Q; Kleynhans, A; Tan, O; Sutton, SK; Xue, C; Chung, SA; Zhang, Y; Sun, C; Zhang, L; Haber, M; Norris, MD; Fletcher, JI; Liu, T; Dilda, PJ; Hogg, PJ; Cheung, BB; Marshall, GM |
| 2023-10-25 | Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma. | Zhai, L; Balachandran, A; Larkin, R; Seneviratne, JA; Chung, SA; Lalwani, A; Tsubota, S; Beck, D; Kadomatsu, K; Beckers, A; Durink, K; De Preter, K; Speleman, F; Haber, M; Norris, MD; Swarbrick, A; Cheung, BB; Marshall, GM; Carter, DR |
| 2024-01 | MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression. | Salib, A; Jayatilleke, N; Seneviratne, JA; Mayoh, C; De Preter, K; Speleman, F; Cheung, BB; Carter, DR; Marshall, GM |
| 2021-07-06 | Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia | Van Thillo, Q; De Bie, J; Seneviratne, JA; Demeyer, S; Omari, S; Balachandran, A; Zhai, V; Tam, WL; Sweron, B; Geerdens, E; Gielen, O; Provost, S; Segers, H; Boeckx, N; Marshall, GM; Cheung, BB; Isobe, K; Kato, I; Takita, J; Amos, TG; Deveson, IW; McCalmont, H; Lock, RB; Oxley, EP; Garwood, MM; Dickins, RA; Uyttebroeck, A; Carter, DR; Cools, J; de Bock, CE |
| 2022-10-04 | Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectory. | Yuan, X; Seneviratne, JA; Du, S; Xu, Y; Chen, Y; Jin, Q; Jin, X; Balachandran, A; Huang, S; Xu, Y; Zhai, Y; Lu, L; Tang, M; Dong, Y; Cheung, BB; Marshall, GM; Shi, W; Carter, DR; Zhang, C |
